BASF sells marine biopolymers business to Seagarden ASA
BASF SE and the Norwegian company Seagarden ASA signed a contract to transfer the chitosan marine biopolymers business. Chitosan marine biopolymers are used in personal care products and as pharmaceutical ingredients. The transaction is expected to be formally completed by August 2012.
The divestment of the Chitosan business from former Cognis results from the portfolio optimization following the acquisition of Cognis by BASF in 2010. The Chitosan business including the production site in Tromsoe, Norway, will be owned by the Norwegian specialist for natural seafood ingredients, marine bioactives and biopolymers, Seagarden SAS through its subsidiary Chitinor AS. The customers have been informed accordingly and conditions have been fixed to ensure supply reliability through the transition.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
'Living' biofilters could reduce greenhouse gas emissions - Naturally occurring microscopic organisms could cut emissions from Alberta industries
ThromboGenics Opens New U.S. Headquarters - U.S. Organization Continues to Build Ahead of Ocriplasmin’s Planned Launch

Researchers work to create biodegradable bioplastics from food waste - Use of microorganisms to convert food waste into fats, which are then processed into bioplastics
Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions
Adventus Group Establishes Joint Venture for European Expansion with S&B Industrial Minerals
Analytik Jena AG establishes subsidiary in Thailand
Study suggests early exposure to antibiotics may impact development, obesity
Pharming's Ruconest(TM) for HAE granted European Marketing Authorization

Start-up receives €24 million for the development of a potential COVID-19 treatment - EIB backs Atriva Therapeutics
Access and SpePharm Announce Licensing of MuGard for Europe - SpePharm Will Market MuGard in Europe for the Treatment of Oral Mucositis
Sartorius Stedim Biotech and Bosch Packaging Technology Announce Global Collaboration
